Certain social determinants of health, such as heightened financial needs and stress levels, were associated with increased psychoneurological symptoms among patients with breast cancer who were disease survivors, according to data presented during the 50th Annual Oncology Nursing Society Congress.
Data from an adjusted model demonstrated a significant relationship between financial needs (P = .002) and stress (P < .001) with increased psychoneurological symptoms among patients with breast cancer who were disease survivors (n = 74). Stress was also significantly associated with increased fatigue (P = .042), anxiety (P < .001), and sleep disturbance (P = .003).
“Twenty-four to 68% of breast cancer survivors experience co-occurring psychoneurological symptoms,” Zahra A. Barandouzi PhD, RN, an assistant professor at the Nell Hodgson Woodruff School of Nursing at Emory University as well as a member of the Winship Cancer Institute in Atlanta, Georgia, and her coauthors wrote in the presentation. “Psychoneurological symptoms include pain, fatigue, sleep disturbances, depressive symptoms, and anxiety. Psychoneurological symptoms are the lasting effects of cancer and its treatment. [The] burden of psychoneurological symptoms has raised curiosity about the factors influencing its severity.”
To conduct their study, investigators performed a secondary data analysis of the R34 which included 74 patients with breast cancer who were disease survivors. Psychoneurological symptoms were examined via the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 v1.0 questionnaires. Psychoneurological symptom cluster score was determined by taking the average of symptoms.
Individual-level social determinants of health were assessed via a questionnaire which identified needs across 8 domains. Community-level social determinants of health were assessed using the Area Deprivation Index. Statistical analysis was performed using linear regression models, which were created to determine the multidimensional impact of social determinants of health on psychoneurological symptom burden.
At baseline, the mean patient age was 53.95 years (SD ± 9.91) and the mean body mass index was 31.18 (SD ± 6.52). Most patients were non-Hispanic Black (52.70%), were educated at a college level or above (82.44%), and had an Area Deprivation Index of less than 75 (78.08%). Patients had stage 0 or I (52.70%), II (35.13%), or III (12.18%) disease.
Findings from an unadjusted model demonstrated that financial needs were significantly associated with increased fatigue (P = .004), depressive symptoms (P < .001), anxiety (P = .003), pain (P = .0007), and psychoneurological symptoms (P < .001). Stress also displayed a significant association with increased fatigue (P = .002), depressive symptoms (P < .001), anxiety (P < .001), pain (P = .016), sleep disturbance (P = .001), and psychoneurological symptoms (P < .001). Moreover, social connection via the phone was significantly associated with increased fatigue (P = .003) and pain (P = .004).
Alcohol use, transportation needs, physical activity, physical social connections, and Area Deprivation Index were not significantly associated with any of the social determinants of health variables, according to the unadjusted model. In the adjusted model, fatigue was also significantly associated with social connection via the phone (P = .040).
In their discussion, Barandouzi and her coauthors noted the importance of targeted interventions to address these challenges to improve symptom management and enhance the quality of life for patients with breast cancer. Support systems aimed at tackling financial burdens and stress management can also improve symptom relief and outcomes for patients, they added.
“Higher financial needs and stress levels were associated with increased severity of psychoneurological symptoms in breast cancer survivors,” Barandouzi and her coauthors wrote in conclusion. “Although further large-scale studies are necessary to validate these findings, the results underscore the potential impact of these 2 factors on cancer symptoms.”
Disclosures: Barandouzi reported no relevant financial relationships with ineligible companies.
References
Barandouzi ZA, Choi H, Lin Y, Bruner D, Li H. The multidimensional impact of social determinants of health on symptoms in breast cancer survivors. Presented at: 50th Annual Oncology Nursing Society Congress; April 9-April 13, 2025; Denver, CO.
News
Article
Social Determinants of Health Significantly Affect Some Psychoneurological Symptoms in Breast Cancer Survivors
Author(s):
Fact checked by:
Key Takeaways
- Financial needs and stress significantly correlate with increased psychoneurological symptoms in breast cancer survivors.
- Symptoms such as fatigue, anxiety, and sleep disturbances are notably associated with stress and financial needs.
- Social determinants of health, assessed through questionnaires and the Area Deprivation Index, impact symptom burden.
- Targeted interventions addressing financial and stress management could improve symptom relief and quality of life.
- Further large-scale studies are necessary to validate the impact of financial needs and stress on cancer symptoms.
SHOW MORESocial factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.
Breast Cancer | Image Credit:
© Sebastian Kaulitzki – stock.adobe.com
Certain social determinants of health, such as heightened financial needs and stress levels, were associated with increased psychoneurological symptoms among patients with breast cancer who were disease survivors, according to data presented during the 50th Annual Oncology Nursing Society Congress.
Data from an adjusted model demonstrated a significant relationship between financial needs (P = .002) and stress (P < .001) with increased psychoneurological symptoms among patients with breast cancer who were disease survivors (n = 74). Stress was also significantly associated with increased fatigue (P = .042), anxiety (P < .001), and sleep disturbance (P = .003).
“Twenty-four to 68% of breast cancer survivors experience co-occurring psychoneurological symptoms,” Zahra A. Barandouzi PhD, RN, an assistant professor at the Nell Hodgson Woodruff School of Nursing at Emory University as well as a member of the Winship Cancer Institute in Atlanta, Georgia, and her coauthors wrote in the presentation. “Psychoneurological symptoms include pain, fatigue, sleep disturbances, depressive symptoms, and anxiety. Psychoneurological symptoms are the lasting effects of cancer and its treatment. [The] burden of psychoneurological symptoms has raised curiosity about the factors influencing its severity.”
To conduct their study, investigators performed a secondary data analysis of the R34 which included 74 patients with breast cancer who were disease survivors. Psychoneurological symptoms were examined via the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 v1.0 questionnaires. Psychoneurological symptom cluster score was determined by taking the average of symptoms.
Individual-level social determinants of health were assessed via a questionnaire which identified needs across 8 domains. Community-level social determinants of health were assessed using the Area Deprivation Index. Statistical analysis was performed using linear regression models, which were created to determine the multidimensional impact of social determinants of health on psychoneurological symptom burden.
At baseline, the mean patient age was 53.95 years (SD ± 9.91) and the mean body mass index was 31.18 (SD ± 6.52). Most patients were non-Hispanic Black (52.70%), were educated at a college level or above (82.44%), and had an Area Deprivation Index of less than 75 (78.08%). Patients had stage 0 or I (52.70%), II (35.13%), or III (12.18%) disease.
Findings from an unadjusted model demonstrated that financial needs were significantly associated with increased fatigue (P = .004), depressive symptoms (P < .001), anxiety (P = .003), pain (P = .0007), and psychoneurological symptoms (P < .001). Stress also displayed a significant association with increased fatigue (P = .002), depressive symptoms (P < .001), anxiety (P < .001), pain (P = .016), sleep disturbance (P = .001), and psychoneurological symptoms (P < .001). Moreover, social connection via the phone was significantly associated with increased fatigue (P = .003) and pain (P = .004).
Alcohol use, transportation needs, physical activity, physical social connections, and Area Deprivation Index were not significantly associated with any of the social determinants of health variables, according to the unadjusted model. In the adjusted model, fatigue was also significantly associated with social connection via the phone (P = .040).
In their discussion, Barandouzi and her coauthors noted the importance of targeted interventions to address these challenges to improve symptom management and enhance the quality of life for patients with breast cancer. Support systems aimed at tackling financial burdens and stress management can also improve symptom relief and outcomes for patients, they added.
“Higher financial needs and stress levels were associated with increased severity of psychoneurological symptoms in breast cancer survivors,” Barandouzi and her coauthors wrote in conclusion. “Although further large-scale studies are necessary to validate these findings, the results underscore the potential impact of these 2 factors on cancer symptoms.”
Disclosures: Barandouzi reported no relevant financial relationships with ineligible companies.
References
Barandouzi ZA, Choi H, Lin Y, Bruner D, Li H. The multidimensional impact of social determinants of health on symptoms in breast cancer survivors. Presented at: 50th Annual Oncology Nursing Society Congress; April 9-April 13, 2025; Denver, CO.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Latest CME
View AllCommunity Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Apr 8th 2025 - May 14th 2025
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Apr 7th 2025 - Apr 8th 2026
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Apr 8th 2025 - May 14th 2025
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Apr 7th 2025 - Apr 8th 2026
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Apr 8th 2025 - May 14th 2025
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Apr 7th 2025 - Apr 8th 2026
Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’
DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Five Under 5: Top Oncology Videos for the Week of 4/13
The OncFive: Top Oncology Articles for the Week of 4/13
Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’
DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Five Under 5: Top Oncology Videos for the Week of 4/13
The OncFive: Top Oncology Articles for the Week of 4/13
Latest Conference Coverage
Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM
Application of Real-World Evidence in Selecting CAR T in R/R MM
Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT
Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer